Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence.

Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T.

Patient Prefer Adherence. 2016 Jun 8;10:1025-35. doi: 10.2147/PPA.S102760. eCollection 2016.

2.

Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States.

Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T.

Patient Prefer Adherence. 2016 Jan 21;10:45-55. doi: 10.2147/PPA.S93320. eCollection 2016.

3.

Rhythmic Aortic Contractions Induced by Electrical Stimulation In Vivo in the Rat.

Sahibzada N, Mangel AW, Tatge JE, Dretchen KL, Franz MR, Virmani R, Gillis RA.

PLoS One. 2015 Jul 1;10(7):e0130255. doi: 10.1371/journal.pone.0130255. eCollection 2015.

4.

Assessment of treatment response in chronic constipation clinical trials.

Ervin CM, Fehnel SE, Baird MJ, Carson RT, Johnston JM, Shiff SJ, Kurtz CB, Mangel AW.

Clin Exp Gastroenterol. 2014 Jun 3;7:191-8. doi: 10.2147/CEG.S58321. eCollection 2014.

5.

From depolarization-dependent contractions in gastrointestinal smooth muscle to aortic pulse-synchronized contractions.

Marion SB, Mangel AW.

Clin Exp Gastroenterol. 2014 Mar 28;7:61-6. doi: 10.2147/CEG.S60448. eCollection 2014. Review.

6.

Clinical trials in irritable bowel syndrome: a review.

Ervin CM, Mangel AW.

Rev Recent Clin Trials. 2013 Mar;8(1):9-22. Review.

PMID:
23130604
7.

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.

Mangel AW, Hicks GA.

Clin Exp Gastroenterol. 2012;5:1-10. doi: 10.2147/CEG.S23274. Epub 2012 Jan 12.

8.

Depolarization-stimulated contractility of gastrointestinal smooth muscle in calcium-free solution: a review.

Evans ED, Mangel AW.

ISRN Gastroenterol. 2011;2011:692528. doi: 10.5402/2011/692528. Epub 2010 Nov 21.

9.

End points in irritable bowel syndrome.

Mangel AW, Fehnel SE.

Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):293-5. doi: 10.1586/egh.11.13. No abstract available.

PMID:
21651345
10.

Urgency as an Endpoint in Irritable Bowel Syndrome.

Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE.

Gastroenterology Res. 2011 Feb;4(1):9-12. Epub 2011 Jan 20.

11.

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study.

Goldberg M, Li YP, Johanson JF, Mangel AW, Kitt M, Beattie DT, Kersey K, Daniels O.

Aliment Pharmacol Ther. 2010 Nov;32(9):1102-12. doi: 10.1111/j.1365-2036.2010.04456.x. Epub 2010 Sep 22.

12.

Does Timing of Colon Procedures Affect Outcomes in D-IBS Trials?

Wang J, Sherrill B, Hamm LA, Mangel AW.

Gastroenterology Res. 2010 Oct;3(5):185-190. Epub 2010 Sep 20.

13.

Asimadoline in the treatment of irritable bowel syndrome.

Mangel AW, Williams VS.

Expert Opin Investig Drugs. 2010 Oct;19(10):1257-64. doi: 10.1517/13543784.2010.515209. Review.

PMID:
20809870
14.

The FDA and IBS drug development.

Mangel AW.

Am J Gastroenterol. 2009 Dec;104(12):3106; author reply 3106. doi: 10.1038/ajg.2009.445. No abstract available.

PMID:
19956135
15.

Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.

Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE.

Gastroenterology. 2009 Dec;137(6):1944-53.e1-3. doi: 10.1053/j.gastro.2009.08.047. Epub 2009 Aug 23.

16.

Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.

Mangel AW, Chaturvedi P.

Digestion. 2008;78(4):180-6. doi: 10.1159/000185719. Epub 2008 Dec 18.

PMID:
19092244
17.

Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.

Mangel AW, Fehnel SE.

Neurogastroenterol Motil. 2008 Oct;20(10):1086-93. doi: 10.1111/j.1365-2982.2008.01198.x. Review.

PMID:
18826559
18.

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.

Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D.

Aliment Pharmacol Ther. 2008 Jul;28(2):239-49. doi: 10.1111/j.1365-2036.2008.03730.x. Epub 2008 May 7.

19.

Gastrointestinal side effects in chronic opioid users: results from a population-based survey.

Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE.

Aliment Pharmacol Ther. 2008 Jun;27(12):1224-32. doi: 10.1111/j.1365-2036.2008.03689.x. Epub 2008 Mar 21.

20.

Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.

Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW.

Aliment Pharmacol Ther. 2008 Jan 15;27(2):197-206. Epub 2007 Oct 31.

21.

Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.

Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ.

Clin Gastroenterol Hepatol. 2007 May;5(5):534-40. Epub 2007 Apr 11. Review.

PMID:
17428741
22.

Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al.

Mangel AW, Fehnel S.

Am J Gastroenterol. 2006 Dec;101(12):2884-5; author reply 2885-7. No abstract available.

PMID:
17227528
23.

Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome.

Williams RE, Black CL, Kim HY, Andrews EB, Mangel AW, Buda JJ, Cook SF.

Aliment Pharmacol Ther. 2006 Jun 1;23(11):1667-75.

24.

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.

Mangel AW.

Aliment Pharmacol Ther. 2006 Apr 1;23(7):879-81. Review.

25.

Stability of irritable bowel syndrome using a Rome II-based classification.

Williams RE, Black CL, Kim HY, Andrews EB, Mangel AW, Buda JJ, Cook SF.

Aliment Pharmacol Ther. 2006 Jan 1;23(1):197-205.

26.

Global endpoints in functional gastrointestinal disease.

Mangel AW, Fehnel SE.

Aliment Pharmacol Ther. 2005 Dec;22(11-12):1162-3; author reply 1163-4. No abstract available.

27.

Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey.

Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen V, Hamm LR, Cook SF, Tennis P, Mangel AW.

Aliment Pharmacol Ther. 2005 Nov 15;22(10):935-42.

28.

Postinfectious IBS.

Mangel AW.

Am J Gastroenterol. 2005 Mar;100(3):729; author reply 729-30. No abstract available.

PMID:
15743380
29.

Study design issues in irritable bowel syndrome.

Mangel AW.

Aliment Pharmacol Ther. 2004 Jan 1;19(1):141-2. No abstract available.

30.

Calcium-dependent, swelling-activated K+ conductance in human neuroblastoma cells.

Basavappa S, Mangel AW, Boulpaep EL.

Biochem Biophys Res Commun. 2003 Sep 5;308(4):759-63. Erratum in: Biochem Biophys Res Commun. 2006 Feb 17;340(3):1016-7.

PMID:
12927783
31.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
32.

A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.

Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW.

Aliment Pharmacol Ther. 2001 Apr;15(4):525-37.

33.

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.

Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW.

Am J Gastroenterol. 2001 Feb;96(2):455-9.

PMID:
11232690
34.

Mice lacking the dopamine transporter display altered regulation of distal colonic motility.

Walker JK, Gainetdinov RR, Mangel AW, Caron MG, Shetzline MA.

Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G311-8.

35.

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW.

Lancet. 2000 Mar 25;355(9209):1035-40.

PMID:
10744088
36.

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.

Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR.

Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.

37.
38.

Review article: evaluation of drugs in experimental gut distension models.

Pappas TN, Mangel AW, Lawson C.

Aliment Pharmacol Ther. 1999 May;13 Suppl 2:54-6. Review.

39.

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.

Hamm LR, Sorrells SC, Harding JP, Northcutt AR, Heath AT, Kapke GF, Hunt CM, Mangel AW.

Am J Gastroenterol. 1999 May;94(5):1279-82.

PMID:
10235207
40.

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.

Miura M, Lawson DC, Clary EM, Mangel AW, Pappas TN.

Dig Dis Sci. 1999 Jan;44(1):20-4.

PMID:
9952218
41.

Activation of calcium channels by cAMP in STC-1 cells is dependent upon Ca2+ calmodulin-dependent protein kinase II.

Basavappa S, Mangel AW, Scott L, Liddle RA.

Biochem Biophys Res Commun. 1999 Jan 27;254(3):699-702.

PMID:
9920804
42.

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome.

Harding JP, Hamm LR, Ehsanullah RS, Heath AT, Sorrells SC, Haw J, Dukes GE, Wolfe SG, Mangel AW, Northcutt AR.

Aliment Pharmacol Ther. 1997 Dec;11(6):1073-6.

43.

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.

Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, McSorley D.

J Int Med Res. 1998 Mar-Apr;26(2):76-81.

PMID:
9602985
44.

Management of gallbladder polyps.

Mangel AW.

South Med J. 1997 May;90(5):481-3. Review.

PMID:
9160062
45.

Regulation of cholecystokinin secretion in STC-1 cells by nitric oxide.

Mangel AW, Scott L, Prpic V, Liddle RA.

Am J Physiol. 1996 Oct;271(4 Pt 1):G650-4.

PMID:
8897884
46.

Swelling-activated amino acid efflux in the human neuroblastoma cell line CHP-100.

Basavappa S, Huang CC, Mangel AW, Lebedev DV, Knauf PA, Ellory JC.

J Neurophysiol. 1996 Aug;76(2):764-9.

PMID:
8871197
47.

Beta-adrenergic regulation of cholecystokinin secretion in STC-1 cells.

Scott L, Prpic V, Capel WD, Basavappa S, Mangel AW, Gettys TW, Liddle RA.

Am J Physiol. 1996 Feb;270(2 Pt 1):G291-7.

PMID:
8779971
48.

Depolarization-stimulated cholecystokinin secretion is mediated by L-type calcium channels in STC-1 cells.

Mangel AW, Scott L, Liddle RA.

Am J Physiol. 1996 Feb;270(2 Pt 1):G287-90.

PMID:
8779970
49.

Swelling-induced chloride currents in neuroblastoma cells are calcium dependent.

Basavappa S, Chartouni V, Kirk K, Prpic V, Ellory JC, Mangel AW.

J Neurosci. 1995 May;15(5 Pt 1):3662-6.

50.

Electrophysiology of intestinal cholecystokinin secretion.

Mangel AW.

Regul Pept. 1995 Apr 14;56(2-3):121-9. Review.

PMID:
7652188

Supplemental Content

Loading ...
Support Center